The agonist of PPARγ has been extensively investigated for its anti-inflammatory and neuroprotection in brain ischemia, spinal injury and other CNS injuries, experimental autoimmune encephalomyelitis, Parkinson's disease, and other neurodegenerative diseases. Here, PPARG is linked to neurodegenerative disease.